EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Target-Enhanced Whole-Genome Sequencing Shows Clinical Validity Equivalent to Commercially Available Targeted Oncology Panel

Sangmoon Lee, Jin Roh, Jun Sung Park, Islam Oguz Tuncay, Wonchul Lee, Jung-Ah Kim, Brian Baek-Lok Oh, Jong-Yeon Shin, Jeong Seok Lee, Young Seok Ju, Ryul Kim, Seongyeol Park und 11 weitere

Cancer Research and Treatment · 15.04.2025 · 57 (2) · 350-361

DOI: 10.4143/crt.2024.114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, erschienen am 15.04.2025. Verfasst von Sangmoon Lee und 22 weiteren Autor:innen. Beteiligte Einrichtung: Inocras Inc., San Diego, CA, USA. Hauptthemen laut MEDLINE: Whole Genome Sequencing, Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, Korea Health Industry Development Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Cancer poses a significant global health challenge, demanding precise genomic testing for individualized treatment strategies. Targeted-panel sequencing (TPS) has improved personalized oncology but often lacks comprehensive coverage of crucial cancer alterations. Whole-genome sequencing (WGS) addresses this gap, offering extensive genomic testing. This study demonstrates the medical potential of WGS.Materials and Methods This study evaluates target-enhanced WGS (TE-WGS), a clinical-grade WGS method sequencing both cancer and matched normal tissues. Forty-nine patients with various solid cancer types underwent both TE-WGS and TruSight Oncology 500 (TSO500), one of the mainstream TPS approaches.

Results

TE-WGS detected all variants reported by TSO500 (100%, 498/498). A high correlation in variant allele fractions was observed between TE-WGS and TSO500 (r=0.978). Notably, 223 variants (44.8%) within the common set were discerned exclusively by TE-WGS in peripheral blood, suggesting their germline origin. Conversely, the remaining subset of 275 variants (55.2%) were not detected in peripheral blood using the TE-WGS, signifying them as bona fide somatic variants. Further, TE-WGS provided accurate copy number profiles, fusion genes, microsatellite instability, and homologous recombination deficiency scores, which were essential for clinical decision-making.

Conclusion

TE-WGS is a comprehensive approach in personalized oncology, matching TSO500’s key biomarker detection capabilities. It uniquely identifies germline variants and genomic instability markers, offering additional clinical actions. Its adaptability and cost-effectiveness underscore its clinical utility, making TE-WGS a valuable tool in personalized cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Whole Genome SequencingNeoplasmsBiomarkers, TumorHumansPrecision MedicineHigh-Throughput Nucleotide SequencingFemaleMaleDNA Copy Number VariationsMiddle Aged

Stichwörter der Autor:innen

BiomarkersMutationNeoplasmsPrecision medicineWhole genome sequencing

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Inocras Inc., San Diego, CA, USA.
  • Department of Pathology, Ajou University School of Medicine, Suwon, Korea.
  • Department of Internal Medicine, Ajou University School of Medicine, Suwon, Korea.
  • Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Förderung

  • National Research Foundation of Korea
  • Ministry of Science and ICT
  • Korea Health Industry Development Institute
  • Ministry of Health and Welfare

Zitieren

APA

Lee, S., Roh, J., Park, J. S., Tuncay, I. O., Lee, W., Kim, J. A., Oh, B. B., Shin, J. Y., Lee, J. S., Ju, Y. S., Kim, R., Park, S., Koo, J., Park, H., Lim, J., Connolly-Strong, E., Kim, T. H., Choi, Y. W., Ahn, M. S., …, & Kwon, M. (2025). Target-Enhanced Whole-Genome Sequencing Shows Clinical Validity Equivalent to Commercially Available Targeted Oncology Panel. Cancer Research and Treatment, 57(2), 350-361. https://doi.org/10.4143/crt.2024.114

Vancouver

Lee S, Roh J, Park JS, Tuncay IO, Lee W, Kim JA, et al. Target-Enhanced Whole-Genome Sequencing Shows Clinical Validity Equivalent to Commercially Available Targeted Oncology Panel. Cancer Research and Treatment. 2025;57(2):350-361. doi:10.4143/crt.2024.114

BibTeX
@article{Lee2025,
  author = {Lee, Sangmoon and Roh, Jin and Park, Jun Sung and Tuncay, Islam Oguz and Lee, Wonchul and Kim, Jung-Ah and Oh, Brian Baek-Lok and Shin, Jong-Yeon and Lee, Jeong Seok and Ju, Young Seok and Kim, Ryul and Park, Seongyeol and Koo, Jaemo and Park, Hansol and Lim, Joonoh and Connolly-Strong, Erin and Kim, Tae-Hwan and Choi, Yong Won and Ahn, Mi Sun and Lee, Hyun Woo and Kim, Seokhwi and Kim, Jang-Hee and Kwon, Minsuk},
  title = {Target-Enhanced Whole-Genome Sequencing Shows Clinical Validity Equivalent to Commercially Available Targeted Oncology Panel},
  journal = {Cancer Research and Treatment},
  year = {2025},
  volume = {57},
  number = {2},
  pages = {350--361},
  doi = {10.4143/crt.2024.114}
}
Kostenlos starten →